Pulse Biosciences Inc. News Releases http://investors.pulsebiosciences.com/ Pulse Biosciences Inc. News Releases en Pulse Biosciences Grants Equity Incentive Awards to New Employees http://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-grants-equity-incentive-awards-new-11 HAYWARD, Calif. --(BUSINESS WIRE)--May 15, 2019-- Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System, announced today that the Compensation Committee of the Company’s Board of Wed, 15 May 2019 16:27:00 -0400 Pulse Biosciences Inc. News Releases 7661 Research program explores energy for lesion treatment http://investors.pulsebiosciences.com/news-releases/news-release-details/research-program-explores-energy-lesion-treatment Nano-Pulse Stimulation (“NPS”, Pulse Biosciences) represents novel technology for delivering cellular specific therapy that is being investigated for its potential to treat both benign and malignant dermatologic lesions. NPS involves the delivery of low energy, high voltage, ultra-short Tue, 14 May 2019 12:00:00 -0400 Pulse Biosciences Inc. News Releases 7726 Pulse Biosciences Quarterly Investor Conference Call http://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-quarterly-investor-conference-call-7 Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT HAYWARD, Calif. --(BUSINESS WIRE)--Apr. 30, 2019-- Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company”), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System, today reported recent corporate developments and Tue, 30 Apr 2019 16:34:00 -0400 Pulse Biosciences Inc. News Releases 7641 Pulse Biosciences to Report First Quarter 2019 Operational Highlights and Financial Results http://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-report-first-quarter-2019-operational HAYWARD, Calif. --(BUSINESS WIRE)--Apr. 17, 2019-- Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System today announced that the Company will report first quarter 2019 operational highlights and financial results on Tuesday, April Wed, 17 Apr 2019 19:27:00 -0400 Pulse Biosciences Inc. News Releases 7631 Pulse Biosciences Grants Equity Incentive Awards to New Employees http://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-grants-equity-incentive-awards-new-10 HAYWARD, Calif. --(BUSINESS WIRE)--Apr. 15, 2019-- Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ System, announced today that the Compensation Committee of the Company’s Board of Directors Mon, 15 Apr 2019 17:00:00 -0400 Pulse Biosciences Inc. News Releases 7626 Pulse Biosciences Announces Presentations at the 2019 American Society for Laser Medicine and Surgery Annual Conference http://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-announces-presentations-2019-american-society HAYWARD, Calif. --(BUSINESS WIRE)--Mar. 26, 2019-- Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced that key findings from its clinical programs using Nano-Pulse Stimulation™ (NPS™) technology will be presented Tue, 26 Mar 2019 14:57:00 -0400 Pulse Biosciences Inc. News Releases 7616 Pulse Biosciences Appoints Mitchell Levinson to Board of Directors http://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-appoints-mitchell-levinson-board-directors HAYWARD, Calif. --(BUSINESS WIRE)--Mar. 19, 2019-- Pulse Biosciences, Inc. (NASDAQ:PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced the appointment of Mitchell Levinson to its board of directors. Tue, 19 Mar 2019 08:00:00 -0400 Pulse Biosciences Inc. News Releases 7581 Pulse Biosciences Grants Equity Incentive Awards to New Employees http://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-grants-equity-incentive-awards-new-employees-9 HAYWARD, Calif. --(BUSINESS WIRE)--Mar. 15, 2019-- Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ System, announced today that the Compensation Committee of the Company’s Board of Directors Fri, 15 Mar 2019 16:33:00 -0400 Pulse Biosciences Inc. News Releases 7571 Pulse Biosciences Announces Late Breaking Oral Presentation of Sebaceous Hyperplasia Study Results at the 2019 AAD Annual Meeting http://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-announces-late-breaking-oral-presentation HAYWARD, Calif. --(BUSINESS WIRE)--Mar. 1, 2019-- Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced that clinical results from its recently completed Sebaceous Hyperplasia study will be presented at the American Fri, 01 Mar 2019 08:00:00 -0500 Pulse Biosciences Inc. News Releases 7561 Pulse Biosciences Submits 510(K) to U.S. FDA for CellFX™ System http://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-submits-510k-us-fda-cellfxtm-system HAYWARD, Calif. --(BUSINESS WIRE)--Feb. 28, 2019-- Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System today announced the Premarket Notification 510(k) submission to the U.S. Food and Drug Administration ( FDA ) for its CellFX Thu, 28 Feb 2019 16:00:00 -0500 Pulse Biosciences Inc. News Releases 7556